González JM, et al. – Researchers elicited preferences and risk tolerance among patients and oncologists in the USA for anticancer drugs to treat metastatic colorectal cancer (CRC) (mCRC). This study indicated a potential for improvement in patients’ well–being, in view of the differences in preferences between patients and physicians. For toxicities, such as skin rash and gastrointestinal perforations, initiating or enhancing discussions about patient tolerance seemed to help prescribe treatments that entail more appropriate benefit–risk tradeoffs.